Europese Unie - Nederlands - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Europese Unie - Nederlands - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyoom - hypofyse en hypothalamische hormonen en analogen - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - multiple sclerose, relapsing-remitting - immunosuppressiva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Europese Unie - Nederlands - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - geslachtshormonen en modulatoren van het genitale systeem, - oral contraceptive.

Europese Unie - Nederlands - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochloride - multiple sclerose, relapsing-remitting - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 en 5. 1)orpatients met zich snel ontwikkelende ernstige relapsing-remitting multiple sclerose gedefinieerd door 2 of meer het uitschakelen van de recidieven in één jaar, en met 1 of meer gadolinium aankleurende laesies op de mri van de hersenen of een significante toename in t2-laesies belasting in vergelijking met een eerdere recente mri.

Europese Unie - Nederlands - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopic - andere dermatologische preparaten - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - leflunomide 10 mg - filmomhulde tablet - leflunomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - leflunomide 10 mg - filmomhulde tablet - leflunomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - leflunomide 20 mg - filmomhulde tablet - leflunomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - leflunomide 20 mg - filmomhulde tablet - leflunomide